Capsugel said to explore sale, IPO

Capsugel‘s private equity owner is said to be exploring a sale or initial public offering for the Pfizer (NYSE:PFE) spinout.

A deal could value Capsugel, which makes hard capsules and drug delivery products, at more than $5 billion, Reuters reported, citing “people familiar with the matter.” Private equity shop KKR & Co. (NYSE:KKR) paid $2.38 billion for Capsugel in April 2011.

Morristown, N.J.-based Capsugel’s suitors include 3M Cos. (NYSE:MMM), Danaher (NYSE:DHR), Becton Dickinson & Co. (NYSE:BDX), Thermo Fisher (NYSE:TMO), Bayer (ETR:BAYN) and Catalent (NYSE:CTLT), the sources told Reuters.

The sources asked not to be identified because the sale process is confidential. KKR and 3M declined to comment, while representatives of Capsugel, Danaher, Becton-Dickinson, Thermo Fisher, Bayer and Catalent did not respond to requests for comment, according to the news service.

The post Capsugel said to explore sale, IPO appeared first on MassDevice.

from MassDevice http://ift.tt/1PsUSu9